Background and Aims

Obesity is a worldwide epidemic with a clear-cut tendency for progression, now recognized as a disease. Nevertheless, a non-operative approach for its treatment remains a challenge.

This study evaluated the efficacy of our new obesity-treatment algorithm.

Methods

Twenty-seven patients files with uncomplicated obesity were analyzed. GLP1 analogue Liraglutide (Saxenda) treatment was implemented for all. In 17 patients (63%), Metformin therapy was additionally implemented due to Impaired Fasting Glucose (IFG). Routine professional CGM (Medtronic iPRO2) was performed in most of participants in order to exclude hypoglycemia, mainly at nights. Our specific therapeutic (Gravicentric) algorithm was used, based on several specific food behavior recommendations, combining this therapy with metformin and physical activity guidance.

Results

The mean age was 58.5 years, therapy duration - 10.5 months, body weight before therapy was 97.3 kg, BMI was 32.7 kg/m².

By using our treatment algorithm, we achieved significant reduction in body weight by 6.8 kg and BMI by 2.4 kg/m² on average. No patients received Saxenda doses higher than 1.8 mg/day, while 70% were managed on 1.2 mg per day or less.

Conclusions

Our real-life weight and BMI resembles to the Liraglutide large RCT results (average reduction of weight by 6.5 kg and BMI by 2.4 kg/m²) while using mild–to-moderate Saxenda dose regimens, without clinically significant side effects. No hypoglycemia time-below-range elevation was noticed at CGM investigations. This therapeutic scheme provides us the unique opportunity to achieve maximal effect at minimal dose. It additionally reduces the probability of side effects (including hypoglycemia and ketosis), and cut treatment costs.